174 related articles for article (PubMed ID: 27506696)
1. Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor.
Shiota M; Kiyoshima K; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Takahashi R; Inokuchi J; Tatsugami K; Eto M
J Urol; 2017 Feb; 197(2):308-313. PubMed ID: 27506696
[TBL] [Abstract][Full Text] [Related]
2. Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer.
Wu SC; Kwon D; Jue JS; Chen FV; Velasquez Escobar MC; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
Eur Urol Focus; 2021 Jan; 7(1):142-147. PubMed ID: 31103602
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
4. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
5. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Shah SK; Trump DL; Sartor O; Tan W; Wilding GE; Mohler JL
J Urol; 2009 Feb; 181(2):621-6. PubMed ID: 19091347
[TBL] [Abstract][Full Text] [Related]
7. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
[TBL] [Abstract][Full Text] [Related]
8. Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence.
Izumi K; Ito Y; Miyamoto H; Miyoshi Y; Ota J; Moriyama M; Murai T; Hayashi H; Inayama Y; Ohashi K; Yao M; Uemura H
Oncotarget; 2016 Mar; 7(12):14153-60. PubMed ID: 26885620
[TBL] [Abstract][Full Text] [Related]
9. 5α-reductase inhibitors impact prognosis of urothelial carcinoma.
Wang CS; Li CC; Juan YS; Wu WJ; Lee HY
BMC Cancer; 2020 Sep; 20(1):872. PubMed ID: 32917158
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.
Onozawa M; Miyanaga N; Hinotsu S; Miyazaki J; Oikawa T; Kimura T; Takaoka E; Kawai K; Shimazui T; Sakurai H; Nishiyama H; Akaza H
Jpn J Clin Oncol; 2012 Sep; 42(9):825-30. PubMed ID: 22782963
[TBL] [Abstract][Full Text] [Related]
11. Re: Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor: M. Shiota, K. Kiyoshima, A. Yokomizo, A. Takeuchi, E. Kashiwagi, T. Dejima, R. Takahashi, J. Inokuchi, K. Tatsugami and M. Eto J Urol 2017;197:308-313.
Kim JH; Chung BI
J Urol; 2017 Jul; 198(1):211-212. PubMed ID: 28365365
[No Abstract] [Full Text] [Related]
12. Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review.
Kim A; Kim MS; Ahn JH; Choi WS; Park HK; Kim HG; Paick SH
Aging Male; 2020 Dec; 23(5):971-978. PubMed ID: 31724468
[TBL] [Abstract][Full Text] [Related]
13. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
14. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
15. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.
Seok J; Kwak HJ; Kwak Y; Lee M; Park KS; Kim A; Cho SG
J Transl Med; 2023 Feb; 21(1):129. PubMed ID: 36800968
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2011 Jan; 185(1):67-71. PubMed ID: 21074202
[TBL] [Abstract][Full Text] [Related]
17. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study.
Liedberg F; Hagberg O; Holmäng S; Hosseini Aliabad A; Jancke G; Ljungberg B; Malmström PU; Åberg H; Jahnson S
Scand J Urol; 2015; 49(4):290-5. PubMed ID: 25624049
[TBL] [Abstract][Full Text] [Related]
18. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
19. Positive Association of Male Overactive Bladder Symptoms and Androgen Deprivation: A Nationwide Population-based Cohort Study.
Li JR; Wang SS; Lin CH; DE Groat WC; Cheng CL
Anticancer Res; 2019 Jan; 39(1):305-311. PubMed ID: 30591473
[TBL] [Abstract][Full Text] [Related]
20. Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer.
Kourbanhoussen K; McMartin C; Lodde M; Zlotta A; Bryan RT; Toren P
Eur Urol Focus; 2021 Sep; 7(5):1044-1051. PubMed ID: 33132108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
